27 July 2015 - Deborah Wilkes
Archived
Teva is set to acquire Allergan's Actavis generics business – including the international OTC unit – in a cash and shares deal worth US$40.5 billion. Teva has now abandoned its hostile takeover bid for generics company Mylan.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.